Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 137-148

  Ruhlmann, Christina ^a   Herrstedt, Jørn ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

5 hydroxytryptamine receptor antagonist; Chemotherapy; Emesis; Nausea; Palonosetron hydrochloride; RS 25259 197

Indexed keywords

APREPITANT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; FENTANYL; FLUOROURACIL; GEMCITABINE; GRANISETRON; HYDROMORPHONE; IFOSFAMIDE; IRINOTECAN; LORAZEPAM; METHYLPREDNISOLONE; METOCLOPRAMIDE; MIDAZOLAM; MORPHINE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PALONOSETRON; SEROTONIN ANTAGONIST; TOPOTECAN; TROPISETRON; UNINDEXED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DRUG BINDING; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; HODGKIN DISEASE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; NAUSEA AND VOMITING; OVARY CANCER; PHARMACODYNAMICS; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; ISOQUINOLINES; NAUSEA; QUINUCLIDINES; VOMITING;

EID: 76749163802     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.175     Document Type: Review

References (63)

1. Coates A, Abraham S, Kaye SB et al. On the receiving end - patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19, 203-208 (1983).
2. Griffin AM, Butow PN, Coates AS et al. On the receiving end V: patients perceptions of the side-effects of cancer chemotherapy in 1993. Ann. Oncol. 7, 189-195 (1996).
3. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305, 905-909 (1981).
4. Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmac. 88, 497-499 (1986).
5. Cunningham D, Hawthorn J, Pople A et al. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet 1(8548), 1461-1463 (1987).
6. Hesketh PJ, Murphy WK, Lester EP et al. GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J. Clin. Oncol. 7(6), 700-705 (1989).
7. Marty M, Pouillart P, Scholl S et al. Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N. Engl. J. Med. 322, 816-821 (1990).
8. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs. metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340, 96-99 (1992).
9. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - the aprepitant protocol 052 study group. J. Clin. Oncol. 21, 4112-4119 (2003).
10. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the Neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97, 3090-3098 (2003).
11. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J. Clin. Oncol. 23, 2822-2830 (2005).
12. Schmoll HJ, Aapro MS, Poli-Bigelli S et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann. Oncol. 17, 1000-1006 (2006).
13. Herrstedt J, Apornwirat W, Shaharyar A et al. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J. Clin. Oncol. 27, 5363-5369 (2009).
14. Grunberg SM, Rolski J, Strausz J et al. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 549-558 (2009).
15. Rapport MM, Green AA, Page IH. Partial purification of the vasoconstrictor in beef serum. J. Biol. Chem. 174, 735-741 (1948). •• Reports on the isolation of serotonin.
16. Rapport MM. Serum vasoconstrictor (serotonin). V. The presence of creatinine in the complex. A proposed structure of the vasoconstrictor principle. J. Biol. Chem. 180, 961-969 (1949). •• Reports on the isolation and classification of serotonin.
17. Gaddum JH. Tryptamine receptors. J. Physiol. 119, 363-368 (1952).
18. Gaddum JH, Picarelli ZP. Two kinds of tryptamine receptor. Br. J. Pharmacol. 12, 323-328 (1957).
19. Baez M, Kursar JD, Helton LA, Wainscott DB, Nelson DL. Molecular biology of serotonin receptors. Obes. Res. 3(Suppl. 4), 441S-447S (1995).
20. Wong EHF, Clark R, Leung E et al. The interaction of RS 25259-25197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br. J. Pharmacol. 114, 851-859 (1995). •• Publication of the pharmacologic properties of palonosetron.
21. 3 receptor. Anesth. Analg. 107(2), 469-478 (2008). •• Publication of the pharmacologic properties of palonosetron.
22. Rojas C, Thomas AG, Alt J et al. Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function. Eur. J. Pharmacol. 626(2-3), 193-199 (2010). •• Publication of the pharmacologic properties of palonosetron.
23. 3 receptor antagonist, in vivo. Br. J. Pharmacol. 114, 860-866 (1995). •• Publication of the pharmacologic properties of palonosetron.
24. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl in 4 infusion solutions. Ann. Pharmacother. 38, 1608-1611 (2004).
25. Trissel LA, Zhang YP. Physical and chemical stability of palonosetron HCl with cisplatin, carboplatin, and oxaliplatin during simulated Y-site administration. J. Oncol. Pharm. Pract. 10, 191-195 (2004).
26. Trissel LA, Zhang Y. Palonosetron HCl compatibility and stability with doxorubicin HCl and epirubicin HCl during simulated Y-site administration. Ann. Pharmacother. 39, 280-283 (2005).
27. Trissel LA, Xu QA. Physical and chemical stability of palonosetron HCl with topotecan HCl and irinotecan HCl during simulated Y-site administration. Int. J. Pharm. Compound 9, 238-241 (2005).
28. Trissel LA, Xu QA. Physical and chemical compatibility of palonosetron HCl with lorazepam and midazolam HCl during simulated Y-site administration. Int. J. Pharm. Compound 9, 235-237 (2005).
29. Trissel LA, Zhang Y. Physical and chemical stability of palonosetron hydrochloride with fluorouracil and with gemcitabine hydrochloride during simulated Y-site administration. Int. J. Pharm. Compound. 9, 320-322 (2005).
30. Xu QA, Trissel LA. Physical and chemical stability of palonosetron hydrochloride with cyclophosphamide and ifosfamide during simulated Y-site administration. Am. J. Health Syst. Pharm. 62, 1998-2000 (2005).
31. Trissel LA, Zhang Y, Xu QA. Physical and chemical stability of palonosetron HCl with dacarbazine and methylprednisolone sodium succinate during simulated Y-site administration. Int. J. Pharm. Compound 10, 234-236 (2006).
32. Trissel LA, Zhang Y. Compability and stability of Aloxi (palonosetron hydrochloride) admixed with dexamethasone sodium phosphate. Int. J. Pharm. Compound 10, 398-403 (2004).
33. Xu QA, Trissel LA. Stability of palonosetron hydrochloride with paclitaxel and docetaxel during simulated Y-site administration. Am. J. Health Syst. Pharm. 61, 1596-1598 (2004).
34. Trissel LA, Trusley C, Ben M et al. Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration. Am. J. Health Syst. Pharm. 64, 1209-1213 (2007).
35. Trusley C, Ben M, Kupiec TC et al. Palonosetron physical and chemical stability with metoclopramide and promethazine during simulated Y-site administration. Int. J. Pharm. Compound. 11, 82-85 (2007).
36. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in U.S. and Japanese healthy subjects. J. Clin. Pharmacol. 44, 520-531 (2004).
37. l4C]-palonosetron in healthy human volunteers. Biopharm. Drug Dispos. 25, 329-337 (2004).
38. Hunt TL, Gallagher SC, Cullen MT, Shah AK. Evaluation of safety and pharmacokinetics of consecutive multiple-day dosing of palonosetron in healthy subjects. J. Clin. Pharmacol. 45, 589-596 (2005).
39. Gralla R, Lichinitser M, Van der Vegt S et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized Phase III trial comparing single doses of palonosetron with ondansetron. Ann. Oncol. 14, 1570-1577 (2003). •• Phase III study: palonosetron versus ondansetron in patients receiving moderately emetogenic chemotherapy (MEC).
40. Eisenberg P, Figueroa-Vadillo J, Zamora R et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Results of a Phase III, single-dose trial versus dolasetron. Cancer 98(11), 2473-2482 (2003). •• Phase III study: palonosetron versus dolasetron in patients receiving MEC.
41. Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17, 1441-1449 (2006). •• Phase III study: palonosetron versus ondansetron in patients receiving highly emetogenic chemotherapy (HEC).
42. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, doubledummy, randomised, comparative Phase III trial. Lancet Oncol. 10, 115-124 (2009). •• Phase III study: palonosetron versus granisetron in patients receiving MEC/HEC.
43. Shah AK, Hunt TL, Gallagher SC, Cullen MT. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr. Med. Res. Opin. 21(4), 595-601 (2005).
44. Eisenberg P, MacKintosh FR, Ritch P, Cornett PA, Macciocchi A. Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study. Ann. Oncol. 15, 330-337 (2004).
45. Grote T, Hajdenberg J, Cartmell A, Ferguson S, Ginkel A, Charu V. Combination therapy for chemotherapyinduced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant. J. Support. Oncol. 4, 403-408 (2006).
46. Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. J. Support. Oncol. 4, 467-471 (2006).
47. Navari RM, Einhorn LH, Loehrer PJ et al. A Phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support. Care Cancer 15, 1285-1291 (2007).
48. Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT, Bubalo J. Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer. Support. Care Cancer 15, 1293-1300 (2007).
49. Musso M, Scalone R, Bonanno V et al. Palonosetron (Aloxi® ) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy. Support. Care Cancer 17, 205-209 (2009).
50. Petru E, Andel J, Angleitner-Boubenizek L et al. Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy. Wien. Med. Wochenschr. 158(5-6), 169-173 (2008).
51. Herrington JD, Jaskiewicz AD, Song J. Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9), 2080-2087 (2008).
52. Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG et al. Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch. Med. Res. 39(6), 601-606 (2008).
53. Yu Z, Liu W, Wang L et al. The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a Phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Support. Care Cancer 17, 99-102 (2009).
54. Musso M, Scalone R, Crescimanno A et al. Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT. Bone Marrow Transplant. 45, 123-127 (2009).
55. Massa E, Astara G, Madeddu C et al. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response. Crit. Rev. Oncol. Hematol. 70(1), 83-91 (2009).
56. Grunberg SM, Dugan M, Muss H et al. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support. Care Cancer 17, 589-594 (2009).
57. Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T. Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results. Support. Care Cancer 17(12), 1469-1473 (2009).
58. Maemondo M, Masuda N, Sekine I et al. A Phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann. Oncol. 20(11), 1860-1866 (2009).
59. Segawa Y, Aogi K, Inoue K et al. A Phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann. Oncol. 20(11), 1874-1880 (2009).
60. Raftopoulos H, Bria E, Gralla R, Lesser M, Napolitano B, Giannarelli D. Is there a preferred dose of palonosetron? Results of an abstracted data (AD) meta-analysis (MA) of all eight randomized double-blind (RDB) studies and the impact on guideline considerations. J. Clin. Oncol. 27(15S), (2009) (Abstract 9636).
61. MASCC antiemetic guidelines www.mascc.org
62. ASCO antiemetic guidelines www.asco.org
63. Summary of product characteristics (Aloxi) www.emea.europa.eu/humandocs/ PDFs/EPAR/aloxi/emea-combined-h563en.pdf